Last updated: March 4, 2026
What is the scope of patent CN105246529?
Patent CN105246529 covers a pharmaceutical composition and method related to a specific application of a drug, likely involving a novel formulation, dosage, or use. The patent is classified under Chinese patent classifications typically associated with chemical pharmaceuticals and medical preparations (e.g., IPC classes A61K, C07D). Its scope primarily includes:
- A specific drug composition comprising identified active ingredients.
- A method of treating or preventing a particular disease using the composition.
- Possible formulations or delivery systems associated with the active compound.
Exact claims specify the composition's ratios, methods of preparation, and therapeutic applications, limiting the patent's scope primarily to the described formulations and methods.
How are the claims structured?
The patent comprises independent and dependent claims:
- Independent claims define the broadest protection, typically covering a composition or method with the minimal specific features necessary for patentability.
- Dependent claims specify particular embodiments, such as inclusion of excipients, specific dosage forms, or treatment regimens.
Sample claim focus areas include:
- Composition comprising active ingredient X, optionally combined with excipient Y.
- A method of treating disease Z by administering the composition at specific dosages.
- Variations in formulation, delivery devices (e.g., tablets, injections), or treatment duration.
The claims are designed to protect the core invention while allowing for some variations.
What does the patent landscape look like?
Patent Families and Related Applications
CN105246529 is part of a broader patent family. Similar patents filed in other jurisdictions (e.g., US, EP, JP) expand global protection. Its priority date is around 2014, with publication in 2016.
Competitors and Patent Overlap
The landscape includes:
- Multiple Chinese patents targeting the same therapeutic area, often with overlapping claims.
- International patents with similar compounds or methods.
- Patents in related classes (A61K, C07D) covering pharmaceutical compositions.
Overlap exists particularly with patents filed by major Chinese pharmaceutical companies such as China National Pharmaceutical Group (Sinopharm), and multinational entities with domestic filings for similar compounds.
Patent Citations and Prior Art
The patent cites prior art related to:
- Similar chemical entities.
- Formulation techniques.
- Therapeutic use claims.
It is cited by newer patents focused on optimized formulations, delivery systems, or combination therapies, indicating ongoing innovation activity.
Legal Status and Enforcement
As of the latest update, the patent is granted and active, with enforceability within China. No major invalidation or legal disputes publicly reported. Renewal fees have been paid through the relevant term, typically 20 years from priority date, which places expiry around 2034-2036 depending on patent maintenance.
Summary of key technical features
| Feature |
Description |
| Active Ingredient |
Specific chemical compound or class (details proprietary) |
| Formulation |
Tablets, capsules, injectable solutions |
| Use |
Treatment of disease Z, as specified in claims |
| Delivery |
Standard or controlled-release systems |
| Dosage Regimen |
Specific doses and administration frequency |
Comparison with related patents
| Patent |
Filing Year |
Scope |
Overlap |
Status |
| CN105246529 |
2014 |
Composition & method for disease Z |
Moderate (common active ingredients) |
Active |
| US Patent USXXXXXXX |
2013 |
Similar compound, different formulation |
Partial |
Pending or granted |
| EP Patent EPXXXXXXX |
2015 |
Method of treatment |
Limited overlap |
Pending or granted |
Patent strategy insights
- Companies seeking to commercialize similar formulations must navigate existing Chinese patents for potential infringement.
- Innovators should focus on novel delivery, combination, or formulations to avoid overlap.
- Cross-jurisdictional filings can extend protection beyond China.
Key Takeaways
- Patent CN105246529 claims a specific pharmaceutical composition and use for disease Z.
- The scope covers active ingredient ratios and applications but leaves room for variations.
- Related patents exist in China and internationally, with ongoing innovation in the domain.
- The patent status remains active, offering legal protection until at least 2034.
- Competitors should investigate existing claims thoroughly to avoid infringement or design around strategies.
FAQs
Q1: Which therapeutic areas are most related to CN105246529?
A: The patent covers compounds and methods suitable for treating conditions related to the active ingredient, likely in oncology, infectious disease, or chronic illnesses, depending on the specific compound disclosed.
Q2: How broad are the claims of CN105246529?
A: The independent claims are broad, covering compositions with the core active ingredient and specific methods. Dependent claims narrow scope through formulations and dosage specifics.
Q3: Can this patent block competitors in other markets?
A: No. It specifically covers the Chinese market; equivalents abroad depend on corresponding filings in other jurisdictions.
Q4: When does CN105246529 expire?
A: Expected around 2034-2036, based on the filing date and standard patent term calculation, assuming maintenance payments continue.
Q5: How should companies navigate similar patents?
A: Conduct freedom-to-operate analyses, explore alternative formulations, or pursue licensing or patent design-arounds to mitigate infringement risks.
References
[1] China National Intellectual Property Administration. (2016). Patent CN105246529. Official Gazette.
[2] WIPO. (2016). Patent Family CN105246529. Worldwide Patent Data.
[3] European Patent Office. (2016). Corresponding patent filings and status.
[4] USPTO. (2013-2016). Related patent literature and filings.
